Andrewa JA, Cudkowicz ME, Hardiman O, Meng L, Bian A, Lee J, et al. (2018). VITALITY-ALS, a phase III trial of tirasemtiv, a selective fast skeletal muscle troponin activator, as a potential treatment for patients with amyotrophic lateral sclerosis: study design and baseline characteristics. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration. http://dx.doi.org/10.1080/21678421.2018.1426770.
When the above article was first published online, there were errors in reference citations. This has now been corrected in the online version.
Taylor & Francis apologizes for this error.